Human cytochromes p450 mediating phenacetin 0-deethylation in vitro: Validation of the high affinity component as an index of CYP1A2 activity

Journal of Pharmaceutical Sciences

Volumn 87, Issue 12, 1998, Pages 1502-1507

  Venkatakrishnan, Karthik ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA NAPHTHOFLAVONE; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE 4 HYDROXYLASE; DIMETHYLNITROSAMINE DEMETHYLASE; PHENACETIN; PHENACETIN O DEETHYLASE; SULFAPHENAZOLE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; ENZYME KINETICS; HUMAN; HUMAN CELL; LIVER MICROSOME METABOLISM; PROTEIN EXPRESSION;

BENZOFLAVONES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MICROSOMES, LIVER; OMEPRAZOLE; PHENACETIN; PROTEIN ISOFORMS; REPRODUCIBILITY OF RESULTS; SULFAPHENAZOLE;

EID: 0031793740     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js980255z     Document Type: Article

References (23)

1. Boobis, A. R.; Kahn, G. C.; Whyte, G.; Brodie, M. J.; Davies, D. S. Biphasic O-deethylation of phenacetin and 7-ethoxycoumarin by human and rat liver microsomal fractions. Biochem. Pharmacol. 1981, 30, 2451-2456.
2. Tassaneeyakul, W.; Birkett, D. J.; Veronese, M. E.; McManus, M. I.; Tukey, R. H.; Quattrochi, L. C.; Gelboin, H. V.; Miners, J. O. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J. Pharmacol. Exp. Ther. 1993,265(1), 401-407.
3. von Moltke, L. L.; Greenblatt, D. J.; Duan, S. X.; Schmider, J.; Kudchadker, L.; Fogelman, S. M.; Harmatz, J. S.; Shader, R. I. Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology 1996, 128, 398-407.
4. Sesardic, D.; Boobis, A. R.; Murray, B. P.; Murray Segura, J.; De La Torre, R.; Davies, D. S. Furafylline is a potent and selective inhibitor of cytochrome P450 IA2 in man. Br. J. Clin. Pharmacol. 1990, 29, 651-663.
5. Newton, D. J.; Wang, R. W.; Lu, A. Y. H. Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 1995, 23(1), 154-158.
6. Bourrié, M.; Meunier, V.; Berger, Y.; Fahre, G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. 1996, 277(1), 321-332.
7. Sesardic, D.; Boobis, A. R.; Edwards, R. J.; Davies, D. S. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br. J. Clin. Pharmacol. 1988, 26, 363-372.
8. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994, 270(1), 414-423.
9. Shimada, T.; Mimura, M.; Inoue, K; Nakamura, S.; Oda, H.; Ohmori, S.; Yamazaki, H. Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Arch. Toxicol. 1997, 71, 401-408.
10. Jensen, K. G.; Poulsen, H. E.; Doehmer, J.; Loft, S. Kinetics and inhibition by fluvoxamine of phenacetin O-deethylation in V79 cells expressing human CYP1A2. Pharmacol. Toxicol. 1995, 76, 286-288.
11. Rodrigues, A. D.; Surber, B. W.; Yao, Y.; Wong, S. L.; Roberts, E. M. [O-ethyl14C]Phenacetin O-deethylase activity in human liver microsomes. Drug Metab. Dispos. 1997, 25(9), 10971100.
12. Crespi, C. L. Xenobiotic metabolizing human cells as tools for pharmacological and toxicological research. Adv. in Drug Res. 1995, 26, 179-235.
13. von Moltke, L. L.; Greenblatt, D. J.; Harmatz, J. S.; Shader, R. I. Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 1993, 47, 268-276.
14. von Moltke, L. L.; Greenblatt, D. J.; Cotreau-Bibbo, M. M.; Duan, S. X.; Harmatz, J. S.; Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptakeinhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interaction in vivo. J. Pharmacol. Exp. Ther. 1994,268, 1278-1283.
15. Yamaoka, K.; Nakagawa, T.; Uno, T. Application of Akaike's information criterion in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 1978, 6, 165-175.
16. Ko, J.-W.; Sukhowa, N.; Thacker, D.; Chen, P.; Flockhart, D. A. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab. Dispos. 1997,25, 853-862.
17. Venkatakrishnan, K.; Greenblatt, D. J.; von Moltke, L. L.; Schmider, J.; Harmatz, J. S.; Shader, R. I. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J. Clin. Pharmacol 1998, 38, 112-121.
18. Korzekwa, K. R.; Krishnamachary, N.; Shou, M.; Ogai, A.; Parise, R. A.; Rettie, A. E.; Gonzalez, F. J.; Tracy, T. S. Evaluation of atypical cytochrome P450 kinetics with twosubstrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 1998, 37, 4137-4147.
19. Venkatakrishnan, K.; von Moltke, L. L.; Greenblatt, D. J. Relative quantities of catalytically active CYP2C9 and 2C19 in human liver microsomes: Application of the relative activity factor approach. J. Pharm. Sei. 1998, 87(7), 845853.
20. Inoue, K.; Yamazaki, H.; Imiya, K; Akasaka, S.; Guengerich, F. P.; Shimada, T. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methylhydroxylation and Smephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 1997, 7, 103113.
21. von Moltke, L. L.; Greenblatt, D. J.; Grassi, J. M.; Granda, B. W.; Duan, S. X.; Fogelman, S. M.; Daily, J. P.; Harmatz, J. S.; Shader, R. I. Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir. J. Clin. Pharmacol. 1998, 38(2), 106-111.
22. Veronese, M. E.; Doecke, C. J.; Mackenzie, P. I.; McManus, M. E.; Miners, J. O.; Rees, D. L. P.; Gasser, R.; Meyer, U. A.; Birkett, D. J. Site-directed mutation studies of human liver cytochrome P450 isoenzymes in the CYP 2C subfamily. Biochem. J. 1993, 289, 533-538.
23. Roskos, L. K.; Patel, B. R.; Wrighton, S. A.; Ring, B. J. Use of nonlinear mixed effect modeling to identify the CYP450s metabolizing phenacetin in human liver microsomes (Abstract). ISSXProceedings; International Society for the Study of Xenobiotics: Cabin John, MD, 1997; Vol. 12, p 160.